%0 Journal Article %T A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %A Khosravi, Adnan %A Salimi, Babak %A Esfahani-Monfared, Zahra %A Seifi, Sharareh %A Mirtavoos-Mahyari, Hanifeh %D 2018 %\ 10/01/2018 %V 19 %N 10 %P 2973-2978 %! A Phase IV Efficacy Study of Formeta Plus Carboplatin as First-Line Treatment of Advanced Non-Squamous, Non-Small Cell Lung Cancer in Iran: An Affordable Price with Clinical Benefit %K Non Small Cell Lung Cancer %K Carboplatin %K Pemetrexed %K Chemotherapy %K safety %R 10.22034/APJCP.2018.19.10.2973 %X Background: This study performed to assess the efficacy and safety of Formeta (generic form of Pemetrexed) plusCarboplatin as first-line chemotherapy in advanced stage, non- squamous, non small cell lung cancer ( NSCLC) in Iran.Methods: This was a post marketing single-arm phase IV efficacy study of Formeta (manufactured by Oncomed.,CzechRepublic ) and Carboplatin in chemo-naive advanced non-squamous NSCLC Iranian patients. Patients received up to sixcycles of Formeta (500 mg/m2) combined with Carboplatin (area under the curve: AUC 5) every 3 weeks. The primaryendpoint was the progression free survival (PFS) and secondary endpoints were safety and overall survival (OS).Results: Fifty-two patients were enrolled between June 2014 to January 2016, and 44 patients were evaluable for bothsafety and efficacy. Partial and complete responses were achieved in 19 (36.5 %) and 2 (3.8%) patients, respectivelyas well as stable disease in 8 patients (15.3 %). Median of PFS and OS were 7.9 ± 1.1 months and 12.43±0.6 months,respectively. Anemia was the most prevalent adverse events of this regimen. Grades 3 or 4 of adverse events were notobserved in any patients. Non-hematologic and other grades of hematologic toxicities were generally mild, and therewere no treatment-related deaths. Conclusion: The combination of Formeta and Carboplatin was effective in advancednon-squamous NSCLC and can be a suitable candidate as first-line treatment in these patient’s population. %U https://journal.waocp.org/article_69127_33070ef0de591ee0c8220c9c4a2f77af.pdf